Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
UK Dementia Research Institute at UCL, London, UK.
EMBO Rep. 2020 Mar 4;21(3):e49129. doi: 10.15252/embr.201949129. Epub 2020 Feb 7.
Signalling endosomes are essential for trafficking of activated ligand-receptor complexes and their distal signalling, ultimately leading to neuronal survival. Although deficits in signalling endosome transport have been linked to neurodegeneration, our understanding of the mechanisms controlling this process remains incomplete. Here, we describe a new modulator of signalling endosome trafficking, the insulin-like growth factor 1 receptor (IGF1R). We show that IGF1R inhibition increases the velocity of signalling endosomes in motor neuron axons, both in vitro and in vivo. This effect is specific, since IGF1R inhibition does not alter the axonal transport of mitochondria or lysosomes. Our results suggest that this change in trafficking is linked to the dynein adaptor bicaudal D1 (BICD1), as IGF1R inhibition results in an increase in the de novo synthesis of BICD1 in the axon of motor neurons. Finally, we found that IGF1R inhibition can improve the deficits in signalling endosome transport observed in a mouse model of amyotrophic lateral sclerosis (ALS). Taken together, these findings suggest that IGF1R inhibition may be a new therapeutic target for ALS.
信号内体对于激活的配体-受体复合物的运输及其远端信号转导至关重要,最终导致神经元存活。尽管信号内体运输缺陷与神经退行性变有关,但我们对控制这一过程的机制的理解仍不完整。在这里,我们描述了一种新的信号内体运输调节剂,即胰岛素样生长因子 1 受体(IGF1R)。我们发现 IGF1R 抑制可增加运动神经元轴突中信号内体的速度,无论是在体外还是在体内。这种效应是特异性的,因为 IGF1R 抑制不会改变线粒体或溶酶体的轴突运输。我们的结果表明,这种运输变化与动力蛋白适配器双尾 D1(BICD1)有关,因为 IGF1R 抑制导致运动神经元轴突中 BICD1 的从头合成增加。最后,我们发现 IGF1R 抑制可以改善肌萎缩侧索硬化症(ALS)小鼠模型中观察到的信号内体运输缺陷。总之,这些发现表明 IGF1R 抑制可能是 ALS 的一个新的治疗靶点。